Latest News and Press Releases

SAN FRANCISCO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), and Nanoscope...

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Retinal Gene Therapy Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.Overall world revenue for the Retinal Gene...

Braille Institute to host book talk with Pulitzer Prize finalist, Andrew Leland, author of The Country of the Blind: A Memoir at the End of Sight.

PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US    Symptoms often start in childhood leading to blindness by midlife with no approved...

New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD),...

AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study

New York, USA, May 07, 2024 (GLOBE NEWSWIRE) -- Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight Retinitis pigmentosa is a genetic disorder characterized...